Overview
Myelodysplastic Syndrome is treated with 8 medications in our database, including Revlimid, AZACITIDINE, Decitabine, DECITABINE, Azacitidine, and 3 more. 8 of these have manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by Bristol Myers Squibb, Pilnova Pharma Inc, BluePoint Laboratories, Eisai, Celgene and others. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Myelodysplastic Syndrome treatment below.
Also known as:
FDA & Trial Timeline
10 eventsAbhay Singh, MD MPH — PHASE2
M.D. Anderson Cancer Center — PHASE1, PHASE2
University of Illinois at Chicago — PHASE2
Halia Therapeutics, Inc. — PHASE2
Novartis Pharmaceuticals — PHASE2
Assistance Publique Hopitaux De Marseille — NA
AbbVie — PHASE3
Associazione Qol-one — PHASE2
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
7 availableLenalidomide
Lenalidomide capsules are indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion …
Lenalidomide capsules are indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities
Inqovi
INQOVI is indicated for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-Briti…
INQOVI is indicated for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups
Grafapex
Use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients 1 year of age and older with myelodysplastic syndrom…
Use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients 1 year of age and older with myelodysplastic syndrome (MDS)
Rytelo
treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not respon…
treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA)
Decitabine
for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refract…
for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups
AZACITIDINE
* Patient Copay Amount: $0 per dose for select HCP-administered medications (e.g., OPDIVO, YERVOY, ABRAXANE); $0 per one-month supply for select oral medications (e.g., REVLIMID, SPRYCEL, POMALYST).
VIDAZA
* Patient Copay Amount: Not Publicly Available * Maximum Annual Benefit Limit: Not Publicly Available * Core Eligibility Restrictions: Eligible commercially insured patients; U.S. residents 18 years o
Rare Disease Specialist
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
2 grantsCommunity
No community posts yet. Be the first to share your experience with Myelodysplastic syndrome.
Start the conversation →Latest news about Myelodysplastic syndrome
5 articlesCaregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Myelodysplastic syndrome
What is Myelodysplastic syndrome?
Myelodysplastic Syndrome is treated with 8 medications in our database, including Revlimid, AZACITIDINE, Decitabine, DECITABINE, Azacitidine, and 3 more. 8 of these have manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by Bristol Myers Squibb, Pilnova Pharma Inc, BluePoint Laboratories, Eisai, Celgene and others. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Myelodysplastic Syndrome treatment below.
Are there clinical trials for Myelodysplastic syndrome?
Yes — 8 recruiting clinical trials are currently listed for Myelodysplastic syndrome on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Myelodysplastic syndrome?
25 specialists and care centers treating Myelodysplastic syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Myelodysplastic syndrome?
5 FDA-approved treatments are currently tracked on UniteRare for Myelodysplastic syndrome. See the treatments and support programs sections for copay assistance, eligibility, and contact details.